INMUNOTEK Top-10 according to Pharma Tech Outlook

INMUNOTEK Top-10 according to Pharma Tech Outlook

{$excerpt:n}

10/2020. INMUNOTEK featured by Pharma Tech Outlook

INMUNOTEK is the cover of  Pharma Tech Outlook, a magazine specialized in pharmaceutical technology, after being recognized among the main European providers of immunotherapies. 

According to the magazine, immunotherapy, which is applied to autoimmune and infectious diseases, cancer or allergies, represents one of the best examples of personalized medicine. The immunotherapy sector is very dynamic and in continuous evolution.

Pharma Tech Outlook has included INMUNOTEK among the top-10 European immunotherapy providers that stand out for their technological and innovative strategies, and has highlighted it on the cover of this special issue.

 +info


La entrada INMUNOTEK Top-10 according to Pharma Tech Outlook se publicó primero en Inmunotek.


Source: Inmunotek News

INMUNOTEK at the A TU SALUD awards

INMUNOTEK at the A TU SALUD awards

{$excerpt:n}

09/2020. INMUNOTEK at A TU SALUD awards

INMUNOTEK has been awarded in the ninth edition of the A TU SALUD awards with the mention Immunology, a discipline recognized this year for the first time for its relevance in the current pandemic situation.

The Spanish newspaper LA RAZÓN held the IX edition of the A TU SALUD Awards, the annual event that recognizes the efforts of innovation and research in the field of Health and Medicine in Spain. The event was chaired by the mayor of Madrid, José Luis Martínez Almeida, together with the Madrid Regional Minister of Health, Enrique Ruiz Escudero, and the director of LA RAZÓN, Francisco Marhuenda. The award was collected by the president of INMUNOTEK, José Luis Subiza Garrido-Lestache from the mayor of Madrid.

The award given to INMUNOTEK is a recognition of its work in research and innovation at the service of immunology.

 +info


La entrada INMUNOTEK at the A TU SALUD awards se publicó primero en Inmunotek.


Source: Inmunotek News

MV140 (Uromune) in recurrent urinary tract infections

MV140 (Uromune) in recurrent urinary tract infections

{$excerpt:n}

.

08/2020. Uromune-MV140. A systematic Review

A systematic review on MV140 (Uromune) has been published. All relevant clinical studies published have been considered to globally assess the impact of this vaccine in the treatment of recurrent urinary tract infections.   

MV140 (Uromune) is a sublingual bacterial vaccine developed by INMUNOTEK designed to prevent urinary tract infections in patients with recurrent infections. In the vast majority of cases, these are bacterial infections that cause recurrent cystitis, which mainly affect women. The conventional treatment of this pathology is based on antibiotics.

The review, published in Can Urol Assoc J, assess the degree of evidence on the clinical efficacy of MV140 (Uromune) in the prevention of this type of pathology from published clinical trials. The authors’ s conclusion is that this vaccine can be an alternative to antibiotics to avoid the recurrence of these types of infections.

Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future

J. Curtis Nickel, MD, FRCSC,corresponding author(1), Paula Saz-Leal, PhD,(2) and R. Christopher Doiron, MD(1)

1) Department of Urology, Queen’s University, Kingston, ON, Canada
2) Inmunotek S.L., Alcalá de Henares, Madrid, Spain

Review (pdf)

La entrada MV140 (Uromune) in recurrent urinary tract infections se publicó primero en Inmunotek.


Source: Inmunotek News

INMUNOTEK receives the National Innovation Award

INMUNOTEK receives the National Innovation Award

{$excerpt:n}

07/2020. Awards Presentation Ceremony

INMUNOTEK receives the National Innovation Award from their Majesties the Kings of Spain with the assistance of the Minister of Science and Innovation. The National Innovation Award is the highest award from the Government of Spain for recognizing the entities that make innovation their main business growth strategy. 

On July 3, the ceremony for the National Innovation and Design Awards took place in Valencia (Science Museum). The event was chaired by their Majesties the Kings of Spain, and INMUNOTEK was awarded the National Innovation Award in the SME (Small and Medium-Sized Entities) category.

The award was accepted by the President of INMUNOTEK, Dr. José Luis Subiza Garrido-Lestache in the presence of the Minister of Science and Innovation, other authorities, the jury and guests. The jury highlighted in its resolution the strong economic commitment of INMUNOTEK in R&D+i, constant and maintained over time, with a technological surveillance system that allows it to make better use of its capabilities to increase its competitiveness.

The speeches of King Felipe VI and Minister Pedro Duque highlighted the winners as an example to increase the competitiveness of companies, the creation of quality employment and to have well-prepared entities ready to offer solutions to the challenges of society.

 +info


La entrada INMUNOTEK receives the National Innovation Award se publicó primero en Inmunotek.


Source: Inmunotek News

INMUNOTEK innovative entity granted by BLOCKPCT

INMUNOTEK innovative entity granted by BLOCKPCT

{$excerpt:n}

06/2020. Innovative Entity Certification

INMUNOTEK has received the innovative entity certification issued by BLOCKPCT  

Madrid Activa SAU, managing entity of the TECNOALCALÁ Science and Technology Park, has registered INMUNOTEK as innovative entity in the blockchain network of Spanish Science and Technology parks (BLOCKPCT), promoted by the Association of Science and Technology Parks from Spain (APTE).

The objective of this initiative is to use blockchain technology to develop a certification procedure, in this case, the innovative nature of Spanish companies and entities and thus provide them with greater visibility.

Acces to the register

+info


La entrada INMUNOTEK innovative entity granted by BLOCKPCT se publicó primero en Inmunotek.


Source: Inmunotek News

Supply of Products and COVID-19

Supply of Products and COVID-19

{$excerpt:n}

03/2019. Information regarding COVID-19

INMUNOTEK information note on the supply of its products.  

In these extraordinarily difficult times, we want to assure our prescribers and patients that despite the situation of confinement established in Spain, our company continues to work to fulfill its commitments.

We have adapted our production following the sanitary recommendations to avoid contagion from our essential personnel. We continue to regularly manufacture and supply our treatments to our international partners for delivery to patients.

In addition to the key personnel who come to our facilities, many employees at home telecommute to continue to provide our partners, prescribers and patients with the support required of us.

Our lines of communication are still operational. If you have any questions, contact us at info@inmunotek.com.

The INMUNOTEK team

 


La entrada Supply of Products and COVID-19 se publicó primero en Inmunotek.


Source: Inmunotek News

COVID-19: INMUNOTEK invited by ITTN

COVID-19: INMUNOTEK invited by ITTN

{$excerpt:n}

03/2020. ITTN selects MV130 project

The project presented by INMUNOTEK has been selected in the “International Innovative Technology against COVID-19” an event organized by ITTN (International Technology Transfer Network) under the auspices of CAST (China Association for Science and Technology).  

INMUNOTEK has presented its project MV130 based on TIbV (trained immunity-based vaccines), in the “Roadshow & Matchmaking of International Innovative Technology against COVID-19”. MV130 confers antiviral resistance by stimulating innate immunity through stable metabolic and epigenetic changes on innate immune cells.

ITTN has been working since February 2020 with the support of the Science and Technology Exchange Center of CAST, through different partners such as MyBioGate, INNONATION, Global-tech IP and SPICI, to search for innovative projects that allow the fight against epidemic diseases. More than 300 international projects have been evaluated in relation to proposals against COVID-19.

In a first selection made by various expert committees, seven projects were invited to participate in the first online Roadshow  that took place on March 20th 2020. INMUNOTEK opened the session with its presentation (Dr. Laura Conejero). More than 200 Chinese attendees from biopharmaceutical companies, investment, institutions and experts from Zhejiang, Jiangsu, Shanghai, Shenzhen, Zhuhai and other places in China were present.

+info


La entrada COVID-19: INMUNOTEK invited by ITTN se publicó primero en Inmunotek.


Source: Inmunotek News

INMUNOTEK´s research in Allergy Virtual Issue

INMUNOTEK´s research in Allergy Virtual Issue

{$excerpt:n}

03/2020. Virtual Issue includes INMUNOTEK´s research

Virtual Issue is a collection of recently published articles in Allergy selected by the Editor-in-Chief on a topic of high interest that are made available Free Access by the journal. Its aim is to bring these articles to the attention of Allergy readers and to reach a wider audience, such as doctors and other health care professionals, who do not have daily access to academic journals.

The first Virtual Issue is dedicated to leading research on Biologicals and Allergen Immunotherapy (AIT). In this issue the research article carried out in the Department of Biochemistry and Molecular Biology (Faculty of Chemistry, Complutense University of Madrid) under the direction of Prof. Oscar Palomares, and INMUNOTEK has been included:

Alum impairs tolerogenic properties induced by allergoid‐mannan conjugates inhibiting mTOR and metabolic reprogramming in human DCs

Cristina Benito‐Villalvilla, Irene Soria, Mario Pérez‐Diego, Enrique Fernández‐Caldas, José Luis Subiza, Oscar Palomares

Alum is one of the most widely used adjuvants in AIT and in this study the authors provide mechanistic insights on Alum impairing tolerogenic properties elicited by allergoid-mannan conjugates. 


La entrada INMUNOTEK´s research in Allergy Virtual Issue se publicó primero en Inmunotek.


Source: Inmunotek News

Financial Times features INMUNOTEK

Financial Times features INMUNOTEK

{$excerpt:n}

12/2019. INMUNOTEK en Financial Times

The Financial Times features INMUNOTEK as a successful company capable of overcoming economic and political turbulences in a special report on business and innovation in Spain.  

According to the Financial Times (FT), innovation and competitiveness shield Spanish companies from eventual turbulences associated with the economic cycles or political issues. Companies that promote these values ​​are able to access to external markets, have a sustainable growth and create employment.

As an example, FT features INMUNOTEK in the article How Spanish business rides out political turbulence. FT highlights how INMUNOTEK has consistently increased its sales by about 20 percent a year, both in the depths of Spain’s recession in 2009-2012 and in recent years when the economy forged ahead. 

 


La entrada Financial Times features INMUNOTEK se publicó primero en Inmunotek.


Source: Inmunotek News

myTomorrows and Inmunotek to develop Expanded Access Program

myTomorrows and Inmunotek to develop Expanded Access Program

{$excerpt:n}

12/2019. Expanded Access Program

Joint press release from myTomorrows and Inmunotek

myTomorrows and Inmunotek to develop Expanded Access Program

Amsterdam, The Netherlands and Madrid, Spain, 12 December, 2019 – myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection, and Inmunotek – with headquarters in Madrid, Spain – a global player in allergy and immunity-based bacterial vaccines, today announced a collaboration to develop an Expanded Access Program (EAP) for the unlicensed bacterial vaccine Uromune.
Inmunotek is progressing Uromune in a clinical development program as a vaccine for patients with recurrent Urinary Tract Infections (rUTIs). The Expanded Access Program will support the supply of Uromune, when prescribed on a Named Patient basis.
Steve Glass, COO of myTomorrows said, “I am delighted that myTomorrows has found a partner in Inmunotek. With our unique online platform, combined with our global capabilities of supporting expanded access we aim to accelerate access to a medicine in development and serve patients with an unmet medical need.”

Prof. Jose Luis Subiza, MD, CEO of Inmunotek commented, “This collaboration with myTomorrows will allow Inmunotek to expand its geographical presence, to the benefit of those patients who have no other treatment options available. Also, this collaboration will likely contribute to a better understanding of the unmet needs of patients suffering rUTI’s and support further development for concomitant diseases.”

About Expanded Access Programs
An Expanded Access Program (EAP), also known as Managed Access Program, supports in a compliant and controlled way the treatment with a medicine currently not licensed in a patient’s country of residence. Such treatment can be an option for patients who have a high unmet medical need, have exhausted all registered treatment options and cannot participate in a clinical trial.

About myTomorrows
myTomorrows operates as a two-sided platform. It serves the interests of both patients and healthcare professionals, as well as drug development. On one side, the company provides information on all treatment options to patients and physicians when registered treatments have been exhausted. On the other side, myTomorrows is specialized in expanded access regulations and administration and real-world data collection, evolving scientific clinical development. myTomorrows has gained experience in running over 20 EAPs over the past 5 years, in more than 30 countries across 5 continents. For more information, please visit www.mytomorrows.com.

For enquiries about myTomorrows or expanded access, please contact our medical team via medical@mytomorrows.com.

About Inmunotek
Inmunotek is a pharmaceutical company based in Alcalá de Henares – Madrid (Spain) that researches, develops, manufactures and markets products in the field of Allergy and Immunology for the diagnosis and treatment of allergic and other immune-based diseases in human and veterinary medicine. For more information about Inmunotek, please visit www.inmunotek.com.

For Inmunotek, please contact:

Inmunotek
Dr Miguel Casanovas, Medical Director
mcasanovas@inmunotek.com
T: +34 912 908 942

For myTomorrows, please contact:

myTomorrows
Dr. Michel van Harten, CMO
medical@mytomorrows.com
T: +31 88 5253 888

La entrada myTomorrows and Inmunotek to develop Expanded Access Program se publicó primero en Inmunotek.


Source: Inmunotek News